N4 Pharma (N4P) is developing Nuvec®, a potentially ground-breaking nanoparticle drug delivery technology with possible applications across cancer therapy and immunology. Nuvec® would have the chance to enhance the intracellular uptake of novel medicines, both in the emerging (but potentially disruptive) field of nucleic acids medicine, targeting disease treatment or prevention at the genetic level, as well as for more established therapies and vaccines.
13 Feb 2019
Aiming a magic bullet
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Aiming a magic bullet
N4 Pharma Plc (N4P:LON) | 0.8 0 0.0% | Mkt Cap: 8.16m
- Published:
13 Feb 2019 -
Author:
Emma Ulker -
Pages:
32
N4 Pharma (N4P) is developing Nuvec®, a potentially ground-breaking nanoparticle drug delivery technology with possible applications across cancer therapy and immunology. Nuvec® would have the chance to enhance the intracellular uptake of novel medicines, both in the emerging (but potentially disruptive) field of nucleic acids medicine, targeting disease treatment or prevention at the genetic level, as well as for more established therapies and vaccines.